Megace® ES: megestrol acetate 625mg/5mL oral suspension

About Megace ES

Unhealthy weight

Is Megace ES right
for you?

Megace ES can help

Patient resources

Home Page > References

References

1. Megace^® ES Prescribing Information. Par Pharmaceutical, Inc. 2008.

2. Kotler D. Challenges to diagnosis of HIV-associated wasting. J Acquir Immune Defic Syndr. 2004;37:S280-S283.

3. Food and Drug Administration, Center for Drug Evaluation and Research. Electronic Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations. 28th ed. Rockville, MD: Food and Drug Administration, Center for Drug Evaluation and Research; 2008. http://www.fda.gov/cder/ob/default.htm. Accessed April 16, 2009.

4. NanoCrystal^® Technology Group. Technology Focus Meeting the Challenges of Drug Delivery. King of Prussia, Pa: Elan Drug Delivery Inc.

5. Wanke C, Polsky B, Kotler D. Guidelines for using body composition measurement in patients with human immunodeficiency virus infection. AIDS Patient Care STDs. 2002;16:375-388.

6. Data on File. PAR-MES-006. Par Pharmaceutical, Inc.

7. Wasting Syndrome. AIDS.org. http://www.aids.org/factSheets/519-Wasting-Syndrome.html. Accessed April 16, 2009.

8. Hohman S. Nutrition for HIV/AIDS. Nutrition and Well-Being A to Z Web site. http://www.faqs.org/nutrition/Hea-Irr/HIV-AIDS.html. Accessed May 7, 2009.

9. Nutrition and weight maintenance. Project Inform, HIV Treatment Information Web site. November 2004. http://www.projinf.org/fs/nutrition/html. Accessed May 7, 2009.

10. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: A new definition. Clin Nutr. 2008;2:793-799.

11. Stoke Your Appetite. American Dietetic Association Web site. http://www.eatright.org/cps/rde/xchg/ada/hs.xsl/home_8236_ENU_HTML.htm. Accessed May 25, 2009.

12. Polsky B, Kotler D, Steinhart C. HIV-associated wasting in the HAART era: guidelines for assessment, diagnosis, and treatment. AIDS Patient Care STDs. 2001;15:411-423.

13. Data on File. PAR-MES-014. Par Pharmaceutical, Inc.

14. Data on File. PAR-MES-002. Par Pharmaceutical, Inc.

15. Data on File. PAR-MES-001. Par Pharmaceutical, Inc.

16. Food Effect Working Group of the Biopharmaceutics Coordinating Committee, Office of Pharmaceutical Science. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. Food and Drug Administration, Center for Drug Evaluation and Research Web site. http://www.fda.gov/cder/guidance/5194fnl.pdf. Published December 2002. Accessed May 7, 2009.

17. Megace^® Oral Suspension Prescribing Information. Bristol-Myers Squibb Company. 2007.

18. Wanke C, Gutierrez J, Kristensen A, et al. Safety and efficacy of two preparations of megestrol acetate in HIV-infected individuals with weight loss in Africa, India, and the United States. J Applied Res. 2007;7(3):206-216.

19. Cella DF, VonRoenn J, Lloyd S, et al. The Bristol-Myers anorexia/cachexia recovery instrument (BACRI): a brief assessment of patients’ subjective response to treatment for anorexia/cachexia. Qual Life Res. 1995;4:221-231.

20. Von Roenn JH, Armstrong D, Kotler DP, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med. 1994;121:393-399.

21. Wanke CA, Silva M, Knox TA, et al. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;31:802-805.

22. Medical Encyclopedia: weight loss – unintentional. Medline Plus^® Web site. January 24, 2005. http://www.nlm.nih.gov/medlineplus/ency/article/003107.htm. Accessed May 8, 2009.

23. Oster MH, Enders SR, Samuels SJ, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med. 1994;121:400-408.

24. Tang AM, Jacobson DL, Spiegelman D, et al. Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-infected patients, 1995 to 2003. J Acquir Immune Defic Syndr. 2005;40:70-76.

25. Testa MA, Lenderking WR. The impact of AIDS-associated wasting on quality of life: qualitative issues of measurement and evaluation. J Nutr. 1999;129:282S-289S.

26. Wheeler DA, Gibert CL, Launer CA, et al, and the Terry Beirn Community Programs for Clinical Research on AIDS. Weight loss as a predictor of survival and disease progression in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:80-85.

27. Loss of Appetite. University of Iowa Health Care Web site. http://www.uihealthcare.com/topics/symptoms/symp3216.html. Accessed April 13, 2009.

28. Nutrition and the Immune System. Medical News Today Web site. http://www.medicalnewstoday.com/articles/13904.php. Accessed April 13, 2009.

29. Nemechek PM, Polsky G, Gottlieb MS. Treatment guidelines for HIV-associated wasting. Mayo Clin Proc. 2000;75:386-394.

30. McKinley MJ, Goodman-Block J, Lesser ML, et al. Improved body weight status as a result of nutrition intervention in adult HIV-positive patients. J Am Diet Assoc. 1994;94:1014-1017.

31. Coodley GO, Loveless MO, Nelson HD et al. Endocrine function in the HIV wasting syndrome. J Acquir Immune Defic Syndr. 1994;7:46-51.